Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Quantin

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Alimentary Pharmacology & Therapeutics|September 24, 2024
Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAMLina Hountondji, Stéphanie Faure, Pascale Palassin, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2025
Clinical characteristics and management of long survivors in extensive stage small cell lung cancerElisa Gobbini, Mamadou Hassimiou Diallo, David Pasquier, et al.
Lung Cancer (Amsterdam, Netherlands)|August 25, 2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and GermanyFrank Griesinger, Maurice Pérol, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClaire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
Journal of Clinical Medicine|February 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
JHEP Reports : Innovation in Hepatology|May 4, 2023
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohortLina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2017
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClémence Basse, Sébastien Thureau, Suzanna Bota, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2023
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, et al.
Targeted Oncology|October 18, 2021
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and OutcomesChristos Chouaid, Thomas Filleron, Didier Debieuvre, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Alimentary Pharmacology & Therapeutics|September 24, 2024
Time to use the right classification to predict the severity of checkpoint inhibitor-induced liver injury, as assessed for causality using the updated RUCAMLina Hountondji, Stéphanie Faure, Pascale Palassin, et al.
Lung Cancer (Amsterdam, Netherlands)|March 22, 2025
Clinical characteristics and management of long survivors in extensive stage small cell lung cancerElisa Gobbini, Mamadou Hassimiou Diallo, David Pasquier, et al.
Lung Cancer (Amsterdam, Netherlands)|August 25, 2022
Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and GermanyFrank Griesinger, Maurice Pérol, Nicolas Girard, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 24, 2018
Systemic Therapy in Advanced Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClaire Merveilleux du Vignaux, Eric Dansin, Laurent Mhanna, et al.
Lung Cancer (Amsterdam, Netherlands)|May 21, 2021
Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA)Marie Wislez, Charlotte Domblides, Laurent Greillier, et al.
Journal of Clinical Medicine|February 11, 2023
Stereotactic MR-Guided Radiotherapy for Liver Metastases: First Results of the Montpellier Prospective Registry StudyKarl Bordeau, Morgan Michalet, Aïcha Keskes, et al.
JHEP Reports : Innovation in Hepatology|May 4, 2023
Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohortLina Hountondji, Christophe Ferreira De Matos, Fanny Lebossé, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2017
Multidisciplinary Tumor Board Decision Making for Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective CohortClémence Basse, Sébastien Thureau, Suzanna Bota, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 30, 2023
Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 TrialJames Chih-Hsin Yang, Baohui Han, Emmanuel De La Mora Jiménez, et al.
Targeted Oncology|October 18, 2021
A Real-World Study of Patients with Advanced Non-squamous Non-small Cell Lung Cancer with EGFR Exon 20 Insertion: Clinical Characteristics and OutcomesChristos Chouaid, Thomas Filleron, Didier Debieuvre, et al.
Pageof 9